Market Overview

Essential Thrombocythemia - Pipeline Insight, 2018 - ResearchAndMarkets.com

Share:

The "Essential
Thrombocythemia - Pipeline Insight, 2018"
drug pipelines has
been added to ResearchAndMarkets.com's offering.

'Essential Thrombocythemia - Pipeline Insight, 2018' report offers
comprehensive Insight of the pipeline (under development) therapeutics
scenario and growth prospects across Essential Thrombocythemia
development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Essential Thrombocythemia Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Mentioned

  • Aop Orphan Pharmaceuticals AG
  • F. Hoffmann-La Roche Ltd
  • Galena Biopharma Inc
  • Incyte Corp
  • Italfarmaco SpA
  • MEI Pharma Inc
  • PharmaEssentia Corp

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jjwzqv/essential?w=4

View Comments and Join the Discussion!